MEDIA ADVISORY: Virtual press conference and the WHO information meeting on the composition of influenza virus vaccines for use in the 2025-2026 Northern Hemisphere influenza season, 28 February 2025

No images? Click here Wednesday, 26 February 2025 MEDIA ADVISORY WHO information meeting and a virtual press conference on the composition of influenza virus vaccines for use in the 2025-2026 Northern Hemisphere influenza season When: Friday, 28 February 2025 WHO information session: from 10.00 to 11.30 CET, livestreamed on WHO’s YouTube channel: www.youtube.com/WHO Virtual press conference (VPC): from 13.45 to 14.35 CET (dial-in details below) What: Announcement of the recommendations for the composition of influenza virus vaccines for the 2026-2026 influenza season in the Northern Hemisphere The vaccine composition will be announced in an information session with the WHO and the Global Influenza Surveillance and Response System (GISRS), which will be followed by a virtual press conference (VPC). Join the VPC by Zoom:   Link: https://who.zoom.us/j/91510473209  Password: WHO+28VpC  Join the VPC by phone:  International numbers available: https://who.zoom.us/u/abNxhiBon8  Webinar ID: 915 1047 3209  Numeric passcode for phone access: 110275642  The virtual press conference will be streamed live on YouTube, LinkedIn and X.   WHO Consultation on the Composition of Influenza Virus Vaccines for Use in the 2025-2026 Northern Hemisphere Influenza Season WHO is hosting the consultations for the northern hemisphere influenza season from 24 to 27 February 2025.  Influenza viruses constantly evolve, making it necessary to update vaccines periodically to ensure they remain effective in protecting people. Twice a year, WHO organizes consultations with an advisory group of experts to analyze influenza virus surveillance data generated by the WHO Global Influenza Surveillance and Response System (GISRS).  Based on this analysis, WHO issues recommendations on the composition of influenza vaccines for the following influenza season. These recommendations guide national regulatory authorities and vaccine manufacturers in developing, producing, and licensing influenza vaccines.  Separate meetings are held for the southern and the northern hemisphere. Notes to journalists: Please ensure you enter your name and media outlet (use name/outlet).  Kindly note, only questions from media (one per journalist) are allowed.  When you sign in you will be automatically put in the meeting room. WHO reserves the right to remove any participant whose behaviour causes any disruption.   To ask a question, please click "raise hand" and this will enter you into the queue for questions (it can be found under the tab: participants) or use the chat function on Zoom clearly indicating your media outlet.  Please make sure you have a microphone connected or active on your computer.  Do not ask questions via the chat as we cannot guarantee that we can incorporate them into the Q&A session. Media contact: mediafctc@who.int   You are receiving this NO-REPLY email because you are included on a WHO mail list. If you have been forwarded this update you can click here to subscribe. Journalists may send feedback to WHO Media Team         Share    Tweet    Share    Forward  World Health Organization, Avenue Appia 20, 1202 Geneva 27, Switzerland  Unsubscribe